The Stochastic Oscillator for IGMS moved out of overbought territory on November 22, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 45 similar instances where the indicator exited the overbought zone. In of the 45 cases the stock moved lower. This puts the odds of a downward move at .
IGMS moved below its 50-day moving average on November 22, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IGMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IGMS broke above its upper Bollinger Band on November 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IGMS entered a downward trend on November 10, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IGMS's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 02, 2023. You may want to consider a long position or call options on IGMS as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IGMS just turned positive on October 26, 2023. Looking at past instances where IGMS's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where IGMS advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.247) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (140.845) is also within normal values, averaging (329.780).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IGMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IGMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotechnology company, which develops antibodies for the treatment of cancer
|MFs / NAME||Price $||Chg $||Chg %|
|Fidelity Advisor® Mid Cap Value A|
|Fidelity Advisor Asset Manager® 70% I|
|Timothy Plan Large/Mid Cap Growth I|
|Gabelli Dividend Growth AAA|
|Tortoise Energy Infrastructure and Inc A|
A.I.dvisor indicates that over the last year, IGMS has been loosely correlated with CRSP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IGMS jumps, then CRSP could also see price increases.